Lupin Launches Triple-Combination Inhaler for COPD Care

Limited has introduced Formoflo-G MDI in India after receiving approval from the Drug Controller General of India (DCGI). Lupin describes the product as the world's first fixed-dose triple-combination metered-dose inhaler for chronic obstructive pulmonary disease (COPD). Key Product Details Product Name: Formoflo-G MDI Active Ingredients: Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate Administration: Fixed-dose inhaler for twice-daily use Purpose: Long-term management of moderate to severe COPD in eligible patients The new product expands Lupin's respiratory medicine portfolio by combining three established therapies in a single inhaler. The launch reflects the company's focus on respiratory-care innovation and addressing evolving treatment needs. Managing Director Nilesh Gupta and India Region Formulations President Rajeev Sibal emphasised the importance of making innovative, quality respiratory treatments available to patients. 📊 Market Focus: Investors will watch product adoption, prescription trends and its potential contribution to Lupin's respiratory business. #Lupin #LupinLimited #PharmaNews #PharmaceuticalSector #COPD #RespiratoryCare #HealthcareInnovation #PharmaStocks #StockMarketNews #IndianStockMarket #NiveshResearch Disclaimer: Investment in securities market are subject to market risks. Read all related documents carefully before investing.